• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
PharmGKB summary: voriconazole pathway, pharmacokinetics.药物基因组学知识库摘要：伏立康唑代谢途径、药代动力学。
Pharmacogenet Genomics. 2017 May;27(5):201-209. doi: 10.1097/FPC.0000000000000276.
2
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.艾沙康唑（BAL4815）、伏立康唑和氟康唑对1007株接合菌、念珠菌、曲霉菌、镰刀菌和赛多孢子菌属菌株的体外抗真菌活性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400. doi: 10.1128/AAC.01512-07. Epub 2008 Jan 22.
3
Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection.伏立康唑与氟氯西林在播散性尖端赛多孢菌感染治疗过程中的相互作用。
J Antimicrob Chemother. 2015 Jul;70(7):2171-3. doi: 10.1093/jac/dkv069. Epub 2015 Mar 15.
4
[The role of voriconazole in the treatment of emerging mycoses].伏立康唑在新兴真菌病治疗中的作用
Rev Iberoam Micol. 2007 Sep 30;24(3):228-32. doi: 10.1016/s1130-1406(07)70048-7.
5
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.伏立康唑联合米卡芬净对念珠菌、曲霉菌、赛多孢属菌及茄病镰刀菌的作用。
Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.
6
Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.伏立康唑治疗侵袭性肺假丝酵母菌病的药效学。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02516-17. Print 2018 May.
7
Determination of MICs of aminocandin for Candida spp. and filamentous fungi.氨基卡汀对念珠菌属和丝状真菌的最低抑菌浓度测定。
J Clin Microbiol. 2006 Dec;44(12):4342-4. doi: 10.1128/JCM.01550-06. Epub 2006 Oct 4.
8
Voriconazole: How to Use This Antifungal Agent and What to Expect.伏立康唑：如何使用这种抗真菌药物以及预期效果如何。
Semin Respir Crit Care Med. 2015 Oct;36(5):786-95. doi: 10.1055/s-0035-1562903. Epub 2015 Sep 23.
9
[In vitro antifungal activity of voriconazole: New data after the first years of clinical experience].伏立康唑的体外抗真菌活性：临床应用首年之后的新数据
Rev Iberoam Micol. 2007 Sep 30;24(3):198-208. doi: 10.1016/s1130-1406(07)70043-8.
10
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.广泛代谢型患者的播散性多育赛多孢菌感染：应对药物相互作用和药物基因组学的雷区
Mycoses. 2014 Sep;57(9):572-6. doi: 10.1111/myc.12199. Epub 2014 Apr 24.

引用本文的文献

1
"Crocus Flower": Voriconazole-Induced Hallucinations and Visual Disturbances in a Patient with Recurrent Severe Vulvovaginitis-A Case Report on Irrational Drug Use.“番红花花”：伏立康唑致复发性严重外阴阴道炎患者幻觉及视觉障碍——不合理用药病例报告
Reports (MDPI). 2024 Nov 22;7(4):105. doi: 10.3390/reports7040105.
2
Unexpected voriconazole toxicity due to nirmatrelvir/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring.因奈玛特韦/利托那韦导致的伏立康唑意外毒性：药物相互作用及治疗药物监测作用的病例报告
Front Pharmacol. 2025 Jun 12;16:1616061. doi: 10.3389/fphar.2025.1616061. eCollection 2025.
3
In vitro screening of UGT2B10 in silico prioritized putative ligands from drugs used in the pediatric hematopoietic stem cell transplantation setting.体外筛选 UGT2B10 在儿童造血干细胞移植环境中使用的药物的潜在配体的计算机预测。
Pharmacol Res Perspect. 2024 Dec;12(6):e70011. doi: 10.1002/prp2.70011.
4
Influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.影响维吾尔族儿科患者异基因造血干细胞移植后伏立康唑肝损伤的危险因素。
BMC Pediatr. 2024 May 3;24(1):299. doi: 10.1186/s12887-024-04625-1.
5
Electrochemical Simulation of Phase I Hepatic Metabolism of Voriconazole Using a Screen-Printed Iron(II) Phthalocyanine Electrode.使用丝网印刷酞菁铁（II）电极对伏立康唑的I期肝脏代谢进行电化学模拟。
Pharmaceutics. 2023 Nov 4;15(11):2586. doi: 10.3390/pharmaceutics15112586.
6
A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.UDP-葡糖醛酸基转移酶 2B10 在儿科造血干细胞移植环境中药物解毒中的潜在作用：一项计算机研究。
BMC Mol Cell Biol. 2022 Jan 21;23(1):5. doi: 10.1186/s12860-021-00402-5.
7
Old and New Calcineurin Inhibitors in Lupus Nephritis.狼疮性肾炎中的新旧钙调神经磷酸酶抑制剂
J Clin Med. 2021 Oct 21;10(21):4832. doi: 10.3390/jcm10214832.
8
CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.CYP2C19 表型与体质量指导下的伏立康唑在造血干细胞移植后婴儿和儿童中的起始剂量。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0062321. doi: 10.1128/AAC.00623-21.
9
Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.应用基于生理的药代动力学模型来表征伏立康唑在儿童中的时间依赖性代谢并支持剂量优化。
Front Pharmacol. 2021 Mar 17;12:636097. doi: 10.3389/fphar.2021.636097. eCollection 2021.
10
Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?将药物基因组学应用于抗真菌药物的选择和剂量确定：我们做到了吗？
Curr Fungal Infect Rep. 2020 Mar;14(1):63-75. doi: 10.1007/s12281-020-00371-w. Epub 2020 Jan 16.

本文引用的文献

1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.临床药物遗传学实施联盟（CPIC） CYP2C19 和伏立康唑治疗指南。
Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18.
2
Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.细胞色素P450 2C19基因多态性对伏立康唑临床疗效的影响：一项系统评价和荟萃分析
Eur J Clin Pharmacol. 2016 Oct;72(10):1185-1193. doi: 10.1007/s00228-016-2089-y. Epub 2016 Jul 8.
3
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.CYP2C19 *17/*17基因型与伏立康唑相关鳞状细胞癌风险的关联
JAMA Dermatol. 2016 Jun 1;152(6):719-20. doi: 10.1001/jamadermatol.2016.0351.
4
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.CYP2C19基因多态性对成年侵袭性真菌感染患者伏立康唑给药及血药浓度的影响。
Int J Antimicrob Agents. 2016 Feb;47(2):124-31. doi: 10.1016/j.ijantimicag.2015.12.003. Epub 2015 Dec 21.
5
Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.基因型指导给药可使接受造血干细胞移植的儿科患者伏立康唑水平达到优化。
Biol Blood Marrow Transplant. 2016 Mar;22(3):482-6. doi: 10.1016/j.bbmt.2015.11.011. Epub 2015 Nov 23.
6
Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients.伏立康唑暴露与肺移植受者皮肤鳞状细胞癌、曲霉菌定植、侵袭性曲霉菌病及死亡风险
Am J Transplant. 2016 Jan;16(1):262-70. doi: 10.1111/ajt.13431. Epub 2015 Sep 3.
7
Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series.细胞色素P450 2C19基因功能获得性单核苷酸变异（CYP2C19*17）可识别危重症患者伏立康唑治疗浓度不足：病例系列研究
Intensive Care Med. 2015 Nov;41(11):2013-4. doi: 10.1007/s00134-015-4002-z. Epub 2015 Aug 4.
8
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.细胞色素P450 2C19基因多态性对与伏立康唑合用时他克莫司药代动力学的影响。
J Clin Pharmacol. 2016 Apr;56(4):408-13. doi: 10.1002/jcph.605. Epub 2015 Oct 8.
9
High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.伏立康唑在一名患有难治性曲霉病且基因型为CYP2C19*17/*17的患者中具有高代谢性N-氧化作用。
Br J Clin Pharmacol. 2015 Oct;80(4):782-4. doi: 10.1111/bcp.12713. Epub 2015 Aug 24.
10
Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.CYP2C19基因与伏立康唑血药浓度的相关性：一项针对印度人的初步回顾性研究。
Int J Clin Pharm. 2015 Oct;37(5):925-30. doi: 10.1007/s11096-015-0143-y. Epub 2015 May 30.

PharmGKB summary: voriconazole pathway, pharmacokinetics.

作者信息

Barbarino Julia M, Owusu Obeng Aniwaa, Klein Teri E, Altman Russ B

机构信息

Departments of aBiomedical Data Science bBioengineering, Stanford University, Stanford, California cIcahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine dDepartment of Medicine, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai eDepartment of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.

出版信息

Pharmacogenet Genomics. 2017 May;27(5):201-209. doi: 10.1097/FPC.0000000000000276.

DOI:10.1097/FPC.0000000000000276
PMID:28277330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5405706/
Abstract
摘要